GRPR Antagonist Radiolabelling Kit for High Purity Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for an optimized method to label NeoB with 68Ga, 67Ga, or 64Cu for imaging purposes that provides high radiochemical purity and is safe for intravenous use in humans, specifically for targeting GRPR-positive tumors.
Innovation Solution
A method involving providing a vial with a GRPR antagonist in dried form, adding a solution of the radioactive isotope, mixing with a buffering agent, and incubating to achieve labeling, with optional pH adjustment, ensuring high radiochemical purity and safety for use as an injectable solution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If radiometal-labelled peptide agonists are used for imaging, then high in vivo radioactivity uptake in targeted tissues is achieved through receptor-mediated endocytosis, but acute biological adverse effects occur and internalization reduces diagnostic specificity
Solution Approach 1:
The patent inverts the conventional agonist approach by using GRPR antagonist peptides instead of agonists. The antagonist binds to GRPR with high affinity on tumor cells but does not trigger internalization or acute biological adverse effects, thereby achieving high tumor uptake through specific binding while avoiding the harmful effects associated with agonist-mediated endocytosis
2Object-affected harmful factors
If GRPR antagonists are used for imaging, then safer clinical use is achieved without acute biological adverse effects, but optimized labeling methods with high radiochemical purity are needed for intravenous administration
Solution Approach 1:
The patent employs parameter changes in the labeling process by optimizing pH conditions (using acetate buffer at pH 4.0-5.0), incubation temperature (95°C for 10 minutes), and buffer composition to achieve high radiochemical purity (>90%) of 68Ga-labeled GRPR antagonist, thereby enabling safe intravenous administration with optimized imaging performance
3Quantity of substance
If GRPR antagonists are used for imaging, then greater doses for potential therapeutic purposes are enabled, but optimized labeling procedures are required to provide high radiochemical purity for intravenous injection
Solution Approach 1:
The patent applies preliminary action by pre-formulating the GRPR antagonist with stabilizing excipients (mannitol, Tween 80, sodium acetate) in a lyophilized kit form, which simplifies the labeling procedure and ensures high radiochemical purity when radiometal is added, thereby facilitating both imaging and potential therapeutic applications with optimized manufacturing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves radiochemical purity of at least 90% for the labeled GRPR antagonist, reducing acute biological adverse effects and enhancing tumor uptake for effective imaging and potential therapeutic purposes.
Implementation Method 1
adding a solution of the radioactive isotope, mixing with a buffering agent, and incubating to achieve labeling
Data Source
AI summary
The present invention relates to methods for radiolabelling GRPR antagonists such as NeoB, and their kits. In particular, the invention to a method for labeling a gastrin-releasing peptide receptor (GRPR) antagonist with a radioactive isotope, preferably 68Ga, 67Ga or 64Cu, said method comprising the steps of: i. providing a first vial comprising said GRPR antagonist in dried form, ii. adding a solution of said radioactive isotope into said first vial, thereby obtaining a solution of said GRPR antagonist with said radioactive isotope, iii. mixing the solution obtained in ii. with at least a buffering agent and incubating it for a sufficient period of time for obtaining said GRPR antagonist labeled with said radioactive isotope, and, iv. optionally, adjusting the pH of the solution.